Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A paper inCellidentifies a subpopulation of intestinal stem cells that are characterized by the expression of LRIG1, which the authors show is a tumour suppressor.
Some of the pathways through which the transcription factor and potential tumour suppressor Cut regulates both differentiation and apoptosis inDrosophila melanogasterhave been identified.
Michael Ohh and colleagues delineate a pathway in which HIF increases the expression of caveolin 1, leading to increased ligand-independent mitogenic signalling by EGFR in cancer cells.
Populations of tumour cells display remarkable phenotypic diversity as a result of both genetic and non-genetic influences. This Review discusses underlying causes of this intra-tumour phenotypic heterogeneity, and why this phenomenon may affect our ability to diagnose and effectively treat tumours.
This review discusses some of the new insights on the development of multiple myeloma that can be gained from considering the evolution of this disease from a Darwinian perspective.
There are multiple subclasses of melanoma that are partly categorized on the basis of their oncogenic molecular drivers. As discussed in this Review, the understanding of the molecular features of melanoma has led to several exciting advances in the treatment of patients with melanoma.
Technological advances in optical coherence tomography (OCT) have enabled this imaging tool to be used to characterize various aspects of tumour biology in vivo. This Innovation article discusses the distinguishing features of OCT, its successful preclinical applications and its potential for clinical adoption.
Recent research has raised hopes for impressively accurate screening for cancer with molecular biomarkers. In this Essay, John A. Baron argues that more sensitive screening tests might be clinically valuable — but that they will present unique issues in implementation and interpretation.